Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Renalytix AI (RNLX) is now available.
Renalytix plc has appointed Joel R. Jung as the Interim Chief Financial Officer following O. James Sterling’s resignation. Jung’s compensation includes a $8,000 monthly base salary and options for 60,000 company shares. These options will vest partially in August 2024, with the remainder vesting monthly over nine months, and accelerate if a change in control occurs. The Consulting Agreement facilitating this arrangement allows for termination with three months’ notice.
Find detailed analytics on RNLX stock on TipRanks’ Stock Analysis page.